(2S,1′S,2′S,3′R)-2- (2′-carboxy-3′-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties

Journal of Medicinal Chemistry

Volumn 45, Issue 17, 2002, Pages 3619-3629

  Collado, Iván ^a   Pedregal, Concepción ^a   Mazón, Angel ^a   Espinosa, Juan Félix ^a   Blanco Urgoiti, Jaime ^b   Schoepp, Darryle D ^c   Wright, Rebecca A ^c   Johnson, Bryan G ^c   Kingston, Ann E ^c  

^a ELI LILLY AND COMPANY   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2' CARBOXY 3' METHYLCYCLOPROPYL)GLYCINE; EGLUMETAD; GLYCINE DERIVATIVE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG; 2-(2'-CARBOXY-3'-METHYLCYCLOPROPYL)GLYCINE; ANXIOLYTIC AGENT; BICYCLO COMPOUND; CYCLOPROPANE DERIVATIVE; DRUG DERIVATIVE; GLYCINE; LIGAND; METABOTROPIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ANALYSIS; TRANQUILIZING ACTIVITY; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; STARTLE REFLEX; STEREOISOMERISM; SYNTHESIS;

ANIMALS; ANTI-ANXIETY AGENTS; BICYCLO COMPOUNDS; CELL LINE; CYCLOPROPANES; GLYCINE; LIGANDS; MODELS, MOLECULAR; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STARTLE REACTION; STEREOISOMERISM;

EID: 0037101811     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0110486     Document Type: Article

References (80)

1. Excitatory amino acid receptor in the vertebrate central nervous system
2. Excitatory amino acid receptors: A gallery of new targets for pharmocological intervention
3. Cloned glutamate receptors
4. Molecular diversity and functions of glutamate receptors
5. Neuropharmacology of AMPA and kainate receptors
6. Ligands for glutamate receptors: Design and therapeutic prospects
7. Excitatory amino acid agonists and antagonists: Pharmacology and therapeutic applications
8. Phenylglycine derivatives as antagonists of metabotropic glutamate receptores
9. The metabotropic glutamate receptors: Structure and functions
10. Pharmacological tools for the investigation of metabotropic glutamate receptors (mGlu receptors): Phenylglycine derivatives and other selective antagonists: Un update
11. Pharmacology and functions of metabotropic glutamate receptors
12. New perspectives for the development of selective metabotropic glutamate receptor ligands
13. Pharmacological agents acting at subtypes of metabotropic glutamate receptors
14. Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist
15. Subtypes of metabotropic excitatory amino acid receptor distinguished by stereoisomers of the rigid glutamate analogue, 1-aminocyclopentane-1,3-dicarboxylate
16. Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740): A potent, selective and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties
17. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors
18. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist
19. LY354740: A systemically active mGlu2/3 receptor agonist
20. Synthesis and pharmacological characterization and molecular modeling of heterobicyclic amino acids related to (LY354740): Identification of LY379268 and LY389795: Two new potent, selective and systemically active agonists for group 2 metabotropic glutamate receptors
21. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists
22. (2S,3S,4S)-α-(carboxycyclopropyl)glycine is a novel agonist of metabotropic glutamate receptors
23. Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in chinese hamster ovary cells
24. Peparation of difluoro analogues of CCGs and their pharmacological evaluations
25. Inversion of cis-substituted α-cyclopropyl acyl anion. Stereoselective entry to the synthesis of a potent metabotropic glutamate agonist, (2S,1′S,2′S)-2-(carboxycyclopropyl) glycine (L-CCG-I), and its 3′-substituted analogues
26. Comparative effect of L-CCG-I, DCG-IV and γ-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes
27. 3H]dicarboxycyclopropyl) glycine binding in rat brain
28. Enantioselective synthesis of 2-(3′-alkyl-2′-carboxycyclopropyl)glycines
29. 1,1-Dimethyl (S) or (R)-4-formyl-2,2-dimethyl-3-oxazolidinone carboxilate: A useful serinal derivative
30. Pharmacophore models of group I and group II metabotropic glutamate receptor agonists. Analysis of conformational, steric, and topological parameters affecting potency and selectivity
31. Synthesis and conformational analyses of glutamate analogues: 2-(2-Carboxy-3-substituted-cyclopropyl)glycines as useful probes for excitatory amino acid receptors
32. Synthesis of trans-3′-substituted-CCG-IV analogues and their characterization to ionotropic glutamate receptors
33. Enantioselective catalytic intramolecular cyclopropanation of allylic α-diazopropionates optimized with dirhodium (II) tetrakis[methyl 2-oxazolidinone-4(S or R)carboxylate]
34. 4
35. Enantioselective, rhodium catalyzed intramolecular cyclopropanations of homoallylic diazoacetates
36. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors
37. Enantioselective intramolecular cyclopropanations of allylic and homoallylic diazoacetamides using chiral dirhodium(II) carboxamide catalysts
38. α-phenylglycinol as chiral auxiliary in diastereoselective Strecker synthesis of α-amino acids
39. α-methoxy-α-trifluoromethylphenylacetic acid, a versatile reagent for the determination of enantiomeric composition of alcohols and amines
40. 2-Substituted ((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonist of group II metabotropic receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution
41. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
42. Serotonin-glutamate interactions: A new target for antipsychotic drugs
43. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus damphetamine motor behavours in rats
44. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine
45. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine
46. The mGlu2/3 receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing
47. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat
48. Anxiolytic and side-effects profile of LY354740: A potent, highly selective, orrally active agonist for group II metabotropic glutamate receptors
49. Potential antianxiety, anti-additive effects of LY354740, a selective group 2 glutamate metabotropic receptors agonist in animal models
50. Disinhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock in rats and pigeons
51. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats
52. Amygdala infusion of LY354740, a group II metabotropic glutamate receptor agonist, blocks fear potentiated startle in rats
53. Stimulation of group II metabotropic glutamate receptor or inhibition of group I ones exerts anxiolytic-like effects in rats
54. The selective mGlR2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal
55. Physiological antagonism between 5-hydroxytryptamine 2A and group II metabotropic glutamate receptors in prefrontal cortex
56. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors
57. Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors
58. Selective activation of group II metabotropic glutamate receptors is protective against excitotoxic neuronal death
59. Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia
60. Selective activation of group II mGlu receptors with LY354740 does not prevent neuronal excitotoxicity
61. Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a group II metabotropic glutamate receptor agonist
62. Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795
63. Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neuron in spinal cord slices from adult rat
64. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: Investigations into possible mechanism of action in vivo
65. Involvement of metabotropic glutamate receptors in excitatory amino acid and GABA release following spinal cord injury in rat
66. Behavioural evidence supporting a differential role for group I and II metabotropic glutamate receptors in spinal nociceptive transmission
67. Periaqueductal gray matter metabotropic glutamate receptors modulate formalin-induced nociception
68. Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice
69. L-glutamate suppresses amyloid β-protein-induced stellation of cultured rat cortical astrocytes
70. Blockade of both epileptogenesis and glutamate release by (1S,3S)-ACPD, a presynaptic glutamate receptor agonist
71. Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist
72. Selective group II glutamate metabotropic receptor agonist LY354740 attenuates pentetrazole- and picrotoxin-induced seizures
73. Anti-epileptic activity of group II metabotropic glutamate receptor agonists (-)-2-oxa-4-aminobicyclo[3.1.0.]-hexane-4,6-dicarboxylate (LY389795)
74. LY354740, a group 2 metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats
75. The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity
76. Glutamatergic influences on the basal ganglia
77. The anxiolytic action of mGlu2/3 receptor agonist LY354740 in fear potentiated startle model in rats is independent of GABAergic modulation and mechanistically distinct from diazepam
78. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors
79. A sensitive and specific mass assay for myo-inositol and inositol phosphates